Literature DB >> 15046871

Neurochemical and behavioral deficits consequent to expression of a dominant negative EphA5 receptor.

A K Halladay1, L Tessarollo, R Zhou, G C Wagner.   

Abstract

The Eph family tyrosine kinase receptors and their ligands have been linked to axon guidance and topographic mapping of the developing central nervous system. More specifically, the EphA5 receptor has been shown to play a role in development of hippocamposeptal, retinotectal and thalamocortical projections. Recently, a line of transgenic mice was developed which expresses a truncated EphA5 receptor lacking a functional tyrosine kinase domain. In a previous study, axonal tracing revealed that medial hippocampal axons in this strain projected laterally and ventrally away from their normal target area. In the current study, both transgenic and wild-type controls were evaluated in unconditioned (rotorod and locomotor activity) and conditioned (water maze and active avoidance) behavior tasks which tested hippocampal and striatal functioning. Compared to controls, the transgenic strain did not show differences in rotorod motor activity but did show a transient deficit in spatial navigation ability and a consistent impairment in active avoidance. The dominant-negative mutant receptor also resulted in a decrease in striatal dopamine and serotonin concentrations with no change in hippocampal monoamines. Collectively, these data suggest that animals expressing a truncated EphA5 receptor show deficits related to striatal functioning.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15046871     DOI: 10.1016/j.molbrainres.2004.01.005

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  9 in total

1.  Canonical BMP-Smad signalling promotes neurite growth in rat midbrain dopaminergic neurons.

Authors:  Shane V Hegarty; Louise M Collins; Aisling M Gavin; Sarah L Roche; Sean L Wyatt; Aideen M Sullivan; Gerard W O'Keeffe
Journal:  Neuromolecular Med       Date:  2014-03-29       Impact factor: 3.843

2.  Changes in attack behavior and activity in EphA5 knockout mice.

Authors:  Ping Chao Mamiya; Zach Hennesy; Renping Zhou; George C Wagner
Journal:  Brain Res       Date:  2008-02-29       Impact factor: 3.252

Review 3.  Axon guidance and synaptic maintenance: preclinical markers for neurodegenerative disease and therapeutics.

Authors:  Ling Lin; Timothy G Lesnick; Demetrius M Maraganore; Ole Isacson
Journal:  Trends Neurosci       Date:  2009-01-21       Impact factor: 13.837

4.  Ephrin-A5 regulates the formation of the ascending midbrain dopaminergic pathways.

Authors:  Margaret A Cooper; Kazuto Kobayashi; Renping Zhou
Journal:  Dev Neurobiol       Date:  2009-01       Impact factor: 3.964

Review 5.  The Role of Ephs and Ephrins in Memory Formation.

Authors:  Monica Dines; Raphael Lamprecht
Journal:  Int J Neuropsychopharmacol       Date:  2016-04-20       Impact factor: 5.176

6.  EphA5 and EphA6: regulation of neuronal and spine morphology.

Authors:  Gitanjali Das; Qili Yu; Ryan Hui; Kenneth Reuhl; Nicholas W Gale; Renping Zhou
Journal:  Cell Biosci       Date:  2016-08-02       Impact factor: 7.133

7.  Semaphorin 3F is a bifunctional guidance cue for dopaminergic axons and controls their fasciculation, channeling, rostral growth, and intracortical targeting.

Authors:  Sharon M Kolk; Rou-Afza F Gunput; Tracy S Tran; Dianne M A van den Heuvel; Asheeta A Prasad; Anita J C G M Hellemons; Youri Adolfs; David D Ginty; Alex L Kolodkin; J Peter H Burbach; Marten P Smidt; R Jeroen Pasterkamp
Journal:  J Neurosci       Date:  2009-10-07       Impact factor: 6.167

8.  Dopaminergic axon guidance: which makes what?

Authors:  Laetitia Prestoz; Mohamed Jaber; Afsaneh Gaillard
Journal:  Front Cell Neurosci       Date:  2012-07-31       Impact factor: 5.505

9.  A genomic pathway approach to a complex disease: axon guidance and Parkinson disease.

Authors:  Timothy G Lesnick; Spiridon Papapetropoulos; Deborah C Mash; Jarlath Ffrench-Mullen; Lina Shehadeh; Mariza de Andrade; John R Henley; Walter A Rocca; J Eric Ahlskog; Demetrius M Maraganore
Journal:  PLoS Genet       Date:  2007-06       Impact factor: 5.917

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.